Search Results | Showing 11 - 20 of 20 results for "GlaxoSmithKline" |
| | | ... close at 2,588.02. LONDON - Britain's leading share index fell nearly 0.5 percent as gloom in heavyweights such as GlaxoSmithKline and Marks & Spencer outweighed gains in BT Group, which sparkled on bid talk. The FTSE 100 closed at 6,606.6 points, down ... |
| | | | ... Britain's FTSE 100 ended a choppy session just inside negative territory, as a last-minute slide in heavyweight GlaxoSmithKline overrode gains in the oil and mining sectors. The FTSE 100 closed at 6,636.8 points, down 4.1 or 0.06 per cent. FRANKFURT ... |
| | | | ... Australia Post. Meanwhile, new executive manager Jarvis is a former director of shared services human resources with GlaxoSmithKline Pharmaceuticals Australasia. The two appointments add a distinctive health care industry backbone to the super fund administration ... |
| | | | ... points to 2,379.10, a five-and-a-half year high. LONDON - Britain's FTSE 100 fell, led down by Astrazeneca and GlaxoSmithKline after the index earlier hit a five-year intraday high. The FTSE 100 closed at 6184.8 points, down 29.8 or 0.48 per cent. FRANKFURT ... |
| | | | ... advanced 2.45 points, or 0.11 per cent, to 2,137.11. LONDON - Britain's FTSE 100 index finished slightly higher, with GlaxoSmithKline leading the way up on the latest legal move to block generic versions of one of its key antidepressants, while miners ... |
| | | | ... Composite Index was up 8.62 points at 2345.36. LONDON - UK stocks fell as heavyweight oil shares and drug maker GlaxoSmithKline slipped. The FTSE 100 closed at 6004.7, down 19.6 points. FRANKFURT - The DAX index ended at 6013.85, down 10.2 points. PARIS ... |
| | | | ... points at 2241.67. LONDON - The FTSE 100 held near 5500 points as firmer oil stocks offset weakness in drugs giant GlaxoSmithKline, which fell after US regulators proposed restrictions on its top-selling asthma drug. The FTSE 100 closed at 5497.9, down ... |
| | | | ... shares closed higher, reversing earlier losses, after reassuring US economic growth figures boosted sentiment and GlaxoSmithKline published a bullish internal earnings forecast. The FTSE 100 closed at 5213.4, up 30.6 points, rising 71.3 points on the ... |
| | | | ... since July's deadly bombs in London as Wall Street turned lower and as investors sold drugmakers AstraZeneca and GlaxoSmithKline in reaction to disappointing earnings from US giant Pfizer. The FTSE 100 closed at 5164.1, down 3.7 points. TOKYO - The Nikkei ... |
| | | | Biotech Biota Holdings is suing global pharmaceutical giant GlaxoSmithKline, alleging that GSK failed to support and promote Biota's flu drug, Relenza. Biota said it had issued a writ in the Victorian Supreme Court. Biota, which licensed Relenza to ... |
|
